Delivery Order SPE2DB22D1202-SPE2DB25FVFF4
- Not listed
- Amerisourcebergen Drug Corp, through its Corporate Office division, has been awarded a $1,705.35 firm fixed price delivery order contract by the Defense Logistics Agency (DLA) Troop Support Medical to provide XYOSTED 100 MG/0.5 ML AUTO-INJ 0.5ML pharmaceutical products. This delivery order is part of a larger indefinite delivery contract (IDC) awarded solely to Amerisourcebergen Drug Corp, with a potential value of $999,999,999.00 and a performance period through December 31, 2025. The IDC...
- The Defense Logistics Agency awarded a delivery order valued at $1,655.80 to AmerisourceBergen Drug Corp for XYOSTED 75 mg/0.5 mL auto-injector units on July 28, 2025, with completion expected by July 29, 2025. This delivery order represents a firm fixed-price purchase with no set-aside designation, indicating the award was made through open competition. The pharmaceutical product will be delivered to the place of performance located in Conshohocken, Pennsylvania, where AmerisourceBergen...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 6, 2025, for the supply of Xyosted 100 mg/0.5 mL auto-injector units valued at $1,731.01. This firm fixed-price delivery order, which is due for completion by August 7, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The award carries no set-aside designation, indicating it was competitively awarded. The pharmaceutical...
- Amerisourcebergen Drug Corp, a for-profit subsidiary of Amerisourcebergen Corporation, has been awarded a firm fixed price delivery order contract worth $1,312.65 by the Defense Logistics Agency (DLA) Troop Support Medical. The contract is for the supply of XYOSTED 100 MG/0.5 ML AUTO-INJ 0.5ML, a specialty pharmaceutical product. This delivery order is part of a larger indefinite delivery contract (IDC) awarded to Amerisourcebergen Drug Corp by DLA, with a potential value of $999,999,999.00...
- Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, has been awarded a $2,362.77 firm fixed price delivery order contract by the Defense Logistics Agency (DLA) to supply the pharmaceutical product XYOSTED 75 MG/0.5 ML AUTO-INJ 0.5ML. This delivery order contract has a completion date of January 26, 2024. Amerisourcebergen Drug Corp serves as the prime contractor for this contract, which is not designated as a set-aside. The award is associated with a larger indefinite...
- The Defense Logistics Agency awarded a $1,629.66 firm fixed-price delivery order to AmerisourceBergen Drug Corp for XYOSTED 75 mg/0.5 mL auto-injector pharmaceutical product on June 18, 2025, with an ultimate completion date of June 20, 2025. This non-set-aside award was made competitively and is being performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Xyosted 100 mg/0.5 ml auto-injector vials with a ceiling value of $1,074.75 and an ultimate completion date of August 12, 2025. This firm fixed-price delivery order is unclassified as a set-aside contract and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a continuation of the company's role as a...
- The Defense Logistics Agency awarded a delivery order valued at $1,524.90 to AmerisourceBergen Drug Corp for XYOSTED 75 mg/0.5 ml auto-injector supplies on July 18, 2025, with completion targeted for July 21, 2025. The contract utilizes firm fixed pricing with no set-aside designation, indicating competitive award based on capability. AmerisourceBergen's corporate office in Conshohocken, Pennsylvania serves as the place of performance for this pharmaceutical delivery order. This delivery order...
- This is a $2,444.49 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of XYOSTED 75 MG/0.5 ML AUTO-INJ 0.5ML, a pharmaceutical product, with a period of performance through July 1, 2025. Amerisourcebergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, designated as...
- The Defense Logistics Agency awarded a $3,443.27 delivery order to AmerisourceBergen Drug Corp for Xyosted 100 mg/0.5 ml auto-injector supplies, with an ultimate completion date of September 8, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The pharmaceutical distributor, headquartered in Conshohocken, Pennsylvania, will perform...
- SPE2DB22D1202Indefinite Delivery Contract
- SPE2DB22D1202-SPE2DB25FVFF4Delivery Order
AmerisourceBergen Drug Corp has been awarded a delivery order valued at $1,358.05 by the Defense Logistics Agency (DLA) for XYOSTED 75 MG/0.5 ML auto-injector pharmaceutical products. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is scheduled for completion by July 23, 2025. The award was issued on July 22, 2025, with the place of performance located in Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate headquarters. This delivery order is a child contract under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. The SPE2DX prime indefinite delivery vehicle serves as a comprehensive global pharmaceutical support contract enabling AmerisourceBergen Drug Corp to supply an extensive range of medications, vaccines, medical devices, and specialized healthcare commodities to support military healthcare programs worldwide. This strategic contract vehicle supports the Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems, positioning AmerisourceBergen Drug Corp as a critical vendor within the military medical supply chain. The DLA has indicated plans to establish Pharmaceutical Prime Vendor Global Program Generation V contracts with multiple regional awards, reflecting the agency's intention to maintain flexible and comprehensive pharmaceutical procurement capabilities across different contractors.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.4k | 7/22/25 |